Indoleamine 2, 3-dioxygenase (IDO) mediated kynurenine pathway of tryptophan degradation is identified as an important immune effector pathway in the tumor cells to escape a potentially effective immune response. IDO affects differentiation and proliferation of T cells, triggering downstream signaling through GCN2, mTOR and AhR. Therefore, IDO is an attractive target for cancer immunotherapy. IDO inhibitors have exhibited potent anticancer activities and might be very useful in combination with chemotherapy, radiotherapy or immunotherapy to trigger rapid regression of aggressive tumors. However, the development of IDO pharmacological inhibitors is proved to be a challenging work. This review highlights recent advances (2010 --2015) in the research related to the role of IDO in immune escape and pathogenic inflammation in cancer, and novel small-molecule IDO inhibitors with an emphasis on their chemical structures and modes of action.
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Immunotherapy is an exciting strategy of cancer therapy
The interactions between immune system and the developments of tumors are dynamic and complex. On one hand, inflammation suppresses the immune responses to actually promote tumors progression; on the other hand, tumor cells are also able to evade or subvert the immune response on the pressure of immune surveillance. It will be effective and critical to breach immune suppressive mechanisms established by tumor cells in the treatment of cancer patients. In 2010, the first therapeutic vaccine Sipuleucel-T was approved for the treatment of metastatic prostate cancer by the Food and Drug Administration (FDA). Since then, immunotherapeutic approaches are unleashed and rapidly expanding worldwide in the field of cancer research. In 2011, the first cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody Ipilimumab was approved for the treatment of metastatic melanoma (MM). phase III trials are currently on-going in cancer immunotherapy. Because of distinguished effectiveness and novelty, cancer immunotherapies promise to be an innovation in the treatment of cancer following operative treatment, chemotherapy, radiotherapy and targeted therapy. IDO affects differentiation and proliferation of T cells, triggering downstream signaling through GCN2, mTOR and AhR (Fig. 1) . Firstly, TRP degradation by IDO may cause a local TRP deprivation in the tissue microenvironment that leads to the accumulation of TRP-tRNA in uncharged conformation. General control non-derepressible 2 (GCN2) is a stressresponse kinase containing an allosteric regulatory site that responds to uncharged tRNA. The activation of GCN2 kinase leads to phosphorylation and attenuation of its downstream target, eukaryotic translation initiation factor-2α (eIF-2α) kinase. Phosphorylated eIF-2α prevents readout of most RNA transcripts and limits protein translation in response to this condition 2 . Secondly, another signaling molecule inhibited due to the absence of TRP is master metabolic regulator mTOR (mTORC1), which is regulatory target of the master amino acid-sensing kinase 1 (GLK1). Local TRP degradation can block GLK1. GLK1 blockade suppresses mTORC1 and is sufficient to trigger autophagy. IDO suppresss mTORC1 as an analogue of the mTOR inhibitor rapamycin to trigger autophagy and anergize T cells in the tumor microenvironment 3 . Thus, TRP depletion in the local microenvironment consumed by IDO can act as a potent regulatory signal via two distinct molecular stress-response pathways, one of which is activated by amine acid insufficiency signaling (GCN2/eIF-2α) and the other of which is blocked by amine acid sufficiency signaling (GLK1/mTORC1 The role of IDO in cancer pathogenesis is more complex than simply acting as a modifier of immune tolerance. Genetic studies in IDO-null mice indicated that IDO contributes to establish the pathogenic inflammatory state, which is hospitable environment for tumor development and metastatic progression 6 . As shown in a classical multistage protocol of DMBA+TPA-induced carcinogenesis, induction of IDO was integral to the pathogenic inflammatory microenvironment, even in the absence of cancer. By the immunoediting definition, there are some nascent tumor cells at least to induce IDO. However, TPA treatment alone was sufficient to induce IDO as an initiating agent to drive the development of tumor, since these mice of DMBA treatment were never exposed to tumor initiation 6 . Another observation showed that the inflammation in IDO-deficient mice don't run rampant and elicited by treatment with a pro-inflammatory agent 7 . In conjunction with results described above, IDO elevation is an early event driven by inflammation, and IDO contributes to the pathogenic chronic inflammation of the tissue microenvironment. IDO is silent in most tissues but highly active in the placenta required for the maternal immune tolerance of the fetus. Many types of cancer cells and tumor environmental cells can express IDO in a constitutive manner or strongly induced by inflammatory mediators such as interferon-gamma (IFN-γ) when host responses against the tumor and produces inflammatory environment. The deregulation of IDO in tumor cells is due to cancer suppressive gene called bridging integrator 1 (Bin1). Bin1 is a c-myc interacting protein with the features of tumor suppressor that interacts with the N-terminal of c-Myc protein to neutralize its transformation and transactivation effect 8 . Clinical observations have suggested that frequent loss or attenuation of Bin1 and high IDO expression are seen in various cancers, containing advanced breast cancer, prostate cancer, melanoma, astrocytoma, neuroblastoma, lymphocytic leukemia and colon cancer, and are associated with worse clinical prognosis in patients with a variety of malignancies 9, 10 . Bin1 can restrict tumor outgrowth and limit tumor immune tolerance through its effect on down regulation of IDO expression. On the contrary, mouse knockout studies indicated that deletion of the Bin1 results in the STAT1 and NF-κB dependent superexpression of IDO following IFN-γ stimulation 11 . Bin1 knockout mice are expected to result in large tumor growth when are transduced with c-myc and mutant ras oncogenes. IDO inhibition can prevent the tumor growth in these mice, suggesting the direct link between Bin1 and IDO activity 11 .
IDO is a key mediator of immune escape and pathogenic inflammation in cancer

Therapeutic strategies and challenges of IDO inhibitors in cancer immunotherapy
Targeting the IDO pathway via inhibition of the IDO enzyme or blocking its downstream signaling effects is a prime target for smallmolecule immunomodulatory drugs in cancer. It has also been widely recognized that IDO inhibitors might be useful in combination with traditional chemotherapeutic drugs or therapeutic cancer vaccines. Damaged or dying tumor cells exposed to chemotherapeutic regimens can express many antigens to activate immune responses against the tumor. However, this almost never triggers a curative immune response against established human tumor, because tumor can rapidly reestablish tolerance following each cycle of chemotherapy by upregulating immunological checkpoints, including IDO 12 . In addition, chemotherapy induces the transient lymphopenia and cytokine-rich environment that may promote T cells to break tolerance to homeostatic recovery 13 . Finally, Chemotherapy can also deplete and blunt regulatory T cells which can generate a short-lived but beneficial anti-tumor immune response 14 . Thus, inhibiting IDO in the period of post-chemotherapy could promote T cells to more receptively break tolerance and potentially enhance the effectiveness of chemotherapeutics by active immunotherapy. Multiple immune inhibitory mechanisms are present concurrently in the tumor microenvironment, so single agent treatments targeting one immunological checkpoint are difficult to achieve optimal efficiency. Allison et al. 15 indicated that IDO is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. IDO blockade strongly synergizes with CTLA-4 antibody ipilimumab, which achieved a striking delay in B16 melanoma tumor growth and increased overall survival. Spranger et al. 16 also reported that multiple inhibitions of IDO, CTLA-4 and PD-1/PD-L1 showed greater effect in activating the immune system and inhibiting tumor growth than either treatment alone. 19 . In mice bearing CT26 colon carcinoma,
Epacadostat also inhibits the growth of IDO-expressing tumors 20 .
Epacadostat is evaluated at present mainly in Phase I/II clinical combination drug trials in gynecological and peritoneal cancers, melanoma, malignant solid tumor, lymphoma, breast, lung, as well as renal cell cancers with CTLA-4 and PD-1/PD-L1 antibodies, respectively. GDC-0919 (NLG919) was obtained by rational structural design based on the X-ray crystal structure for IDO complexed with 4-phenyl-imidazole (PIM). It is a strong competitive IDO inhibitor and potently inhibits IDO pathway in vitro and in cellular assays (K i =7nM, EC 50 =75nM). Treatment with GDC-0919, upon vaccination of B16F10 tumor-bearing mice, resulted in an increase in the T effector cell response, leading to improved antitumor efficacy (~95% reduction in tumor volume) 21 . Combined treatment with GDC-0919 and chemo-radiation therapy enhanced survival in mice bearing intracranial glioblastoma tumors. Chemotherapy treatment alone resulted in collections of perivascular leukocytes within the tumor microenvironment, but no complement deposition. Adding IDO-blockade led to upregulation of vascular cell adhesion molecule-1 (VCAM-1) on vascular endothelium within tumors, and further led to widespread complement deposition at sites of tumor growth 22 . In Phase Ia clinical trial for the treatment of advanced-stage solid tumors, GDC-0919 demonstrated the high dose tolerance (well tolerated up to 800 mg BID on a 21/28 day cycle), but revealed that single-agent therapy with an IDO inhibitor failed to cause tumor eradication and to prevent disease progression (best response was limited to stable disease in 7 out of 17 patients). GDC-0919 is now evaluated in phase Ib in combination with PD-L1 inhibitor atezolizumab 23 .
Structure-based IDO inhibitors design
The inhibitors. IDO is a monomeric heme-containing enzyme. In the PIM-bound X-ray structure, the ligand is bound in a deep binding site with one imidazole nitrogen coordinated to the Fe iron at the distance of 2.1Å and its phenyl ring inside a hydrophobic pocket (pocket A). The PIM binding sites consist of residues Tyr126, Cys129, Val130, Phe163, Phe164, Ser167, Leu234, Gly262, Ser263, Ala264, and the heme ring. Possible hydrogen bonding sites are the Cys129-SH, Ser167-OH, Gly262-CO, Ala264-NH and the heme 7-propionate group. In 2014, two crystal structures of IDO bound to the larger ligands Amg-1 (PDB file "4PK5") and imidazothiazole compound (PDB file "4PK6") were published 25 (Fig. 3) . Another hydrophobic pocket (pocket B) at the entrance of pocket A is provided by multiple residues and the heme ring. In addition to occupy pocket A, the larger ligands can also interact with residues located at pocket B, containing Phe226, Arg231, Ser235, Phe291, Ile354, and Leu384. Moreover, the additional hydrogen bond with the side chain of Arg231 is possible. The ligands occupied both pocket A and pocket B may obtain better inhibitory activities. Röhrig et al. 26 investigated the binding modes of all known IDO inhibitors via docking algorithm EA Dock and developed a pharmacophore model to devise new compounds to be tested for IDO inhibition. Fragment-based approach was also used to design and to optimize small organic molecule inhibitors. Both approaches yielded several novel small-molecular inhibitor scaffolds and the most active compound 1 showed nanomolar inhibitory activity. On the basis of the binding modes between IDO and these ligands, they concluded that an ideal IDO inhibitor should contain the following features: (i) an aromatic ring with at least two cycles, to fill into pocket A. Almost all known IDO inhibitors comply with this rule; (ii) an atom with a free electron pair (such as oxygen, sulfur, or nitrogen) that can coordinate to the Fe iron. The ligands not obeyed this rule generally show low inhibitory activities; (iii) groups in larger ligands that can form van der Waals interactions with the binding sites in the pocket B; (iv) groups in larger ligands that can form hydrogen bond to Ser167, Gly262, Ala264, and Arg231 or to the heme 7-propionate 26 . At the same year, a series of hypoxiatargeting novel IDO hybrid inhibitors have been designed and synthesized by Nakashima et al. 27 . Among these compounds, L-Trptirapazamine hybrid 2 was able to bind the enzyme-substrate complex and showed the potent IDO inhibitory activity with an IC 50 value of 15.3μM. Smith et al. 28 have developed three pharmacophores to search novel IDO inhibitors, coupled with refinement of hits through Kier flexibility scoring and "What-If" docking analysis. Eighteen compounds were tested in vitro, yielding compound 3 (IC 50 : 20μM) with an ester imidamide linker between two aromatic regions, which has much greater interactions with the active site compared to many of the simple IDO inhibitors reported to date. Fragment screening has the capacity to identify novel IDO inhibitors, including those can't identified by enzymatic screening. by screening of the Zenobia fragment library. It forms a coordinated bond with the heme iron to stable the complex through hydrazine rather than through the sulphur in the benzothiazole ring. Phenylhydrazine was 32-fold more potent (IC 50 : 0.25μM) than 2-hydrazinobenzothiazole (4) (IC 50 : 8.0μM) 29 . The enzyme assay indicated that the hydrazine interaction is sufficient for IDO inhibitory, and the benzothiazole group was less favorable for inhibition of IDO, because it may restrict the hydrazine-heme interaction.
Based on the co-crystal structure of IDO with PIM, Huang et al. 30 discovered that 1H-1,2,3-triazole might be a new key pharmacophore of potent IDO inhibitors. The triazole scaffold shares structural similarity with PIM and it replaces the imidazole ring by a triazole ring, which has widely applied in pharmaceuticals. The different series of 1,2,3-triazoles were thus synthesized for screening high efficacy IDO inhibitors, and compound 5 showed potent inhibitory activity with an IC 50 value of 86 μM. Molecular docking studies indicated that substituent group on 4-aryl should not be too large and an electron-withdrawing group near the NH group of the triazoles was prerequisite of inhibitory activities.
IDO inhibitors discovered by HTS
HTS strategy is extensively carried out on library screening by measuring kynurenine formation in enzymatic assay with purified recombinant human IDO protein. The benzylisothiourea derivative 6 was identified as noncompetitive IDO inhibitors via screening campaign. Subsequent optimization of 6 lead to the identification of nanomolar inhibitor 7, which suppressed kynurenine production in A431 cells 31 . Structure-activity relationships (SARs) analysis revealed that the distance from the isothiourea moiety and the halogen atom at the C-4 of phenyl ring were necessary for inhibitory activities. The keto-indole derivative 8 was identified as a potent IDO inhibitor via virtual screening strategy combining various filters including HTS docking 32 . Then, a novel series of IDO inhibitors are synthesized based on this indol-2-yl ethanone scaffold, leading to the compound 9 with an IC 50 value of 13μM 33 . Preliminary SARs analysis revealed an iron coordinating group on the linker is essential to retain inhibitory activity. Methylthiohydantointryptophan (MTH-Trp, 10) was discovered by library screening in 2005. A series of novel tryptoline derivatives were synthesized based on its structure and the most active compound 11 showed potent inhibitory activity with an IC 50 value of 46.1μM 34 .
Matsuno et al. 35 have discovered the anti-hypertensive drug candesartan cilexetil as an IDO inhibitor with an IC 50 of 12μM by screening. This agent is an angiotensin II receptor blocker (ARB) with wide utilities in clinics. A series of candesartan derivatives have subsequently been synthesized and the most active compound 12 showed potent inhibitory activity with an IC 50 value of 1.0μM. SARs analysis and docking results indicated that candesartan derivatives may uniquely bind to the entrance of the active site of IDO, not to the heme ferrous iron. Recently, a series of phenyl benzenesulfonylhydrazides were synthesized in order to improve cellular inhibitory activities of 2-phenyl benzeneethanesulfonylhydrazide 13, which was identified as a potent IDO inhibitor via HTS 36 . The compound 14 showed good inhibitory activity with an IC 50 value of 61nM in vitro and an EC 50 value of 172nM in the HeLa cell. SARs analysis revealed that the interactions between 14 and IDO conclude the coordination of sulfone and heme iron, the hydrogen bonding and hydrophobic interactions.
Natural-source IDO inhibitors
It is well established that various benzoquinone and naphthoquinones display low micromolar activities as IDO inhibitors, e.g. exiguamine A (15) and annulin B (16), suggesting these moieties to be key pharmacophores and likely indolemimetic. Bridewell et al. 37 have tested a series of pyranonaphthoquinone natural products, leading triazole 17 with potent IDO inhibitory activity (IC 50 : 6.0μM) and cellular activity against IDO. . SARs analysis revealed that the orientation of the dioxydihydrothiazine ring fusion to C-14/C-15 is important and the hydroxyl at C-3 is significantly detrimental to inhibitory activity. These results described above have extended the quinone series with IDO inhibitory activities based on natural products.
Many natural alkaloids have also been discovered to be novel IDO inhibitors. Tryptanthrin (indolo [ 
Conclusions and perspectives
The structure of IDO consists of a highly conserved sequence AGGSAG (residues 260-265), which provides conformational flexibility in several proteins. Thus, the main chain of IDO exhibits backbone flexibility and a large conformational change, leading to different active site conformations characterized by larger pocket A and different shapes and sizes of pocket B. Therefore, it is important in the approach of IDO docking studies that protein flexibility and heme interactions could be taken into account. IDO is an intercellular monomeric enzyme constituted by a heme Fe iron center as a site for transferring oxygen atoms into pyrrole ring. IDO is active when the Fe iron is in its reduced ferrous state, so the continuous presence of reductants is necessary to maintain enzyme activity, since IDO is prone to autoxidation. Cytochrome reductases and cytochrome b5 are putative intracellular reducing agents, and these reductants are substituted by methylene blue and ascorbic acid in vitro assay, to keep the Fe iron in its reduced form. A large number of natural IDO inhibitors are redox-cycling compounds. Some experts have presumed these compounds contain problematic functional groups such as quinines, which will not only affect the kynurenine pathway of TRP degradation but also interfere with many other cellular pathways. Therefore, it should be avoided to use these compounds as IDO inhibitors.
IDO is an attractive target for anticancer therapy and the discovery of IDO inhibitors has been intensely ongoing in both academic research laboratories and pharmaceutical organizations. Over the recent five years, several new IDO inhibitor scaffolds have been discovered by structure-based design, HTS, and natural product screening. We hope the information provided herein will be helpful for the development of novel IDO pharmacological inhibitors in the treatment of cancer. 
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